Biotech is making progress on the development of its flagship product made from plants.
NFL Biosciences is preparing its listing on Euronext Growth. The Montpellier-based biotech is launching a global offer of € 5.26 million that can be increased to € 8 million with a price per share of between 3.4 to 4.6 euros. A minimum of € 3.35 million has also already been subscribed.
This funding should enable it to advance the development of its flagship product, NFL-101. This compound, intended for smoking cessation, has validated a phase II / III clinical trial.
An old allergy treatment
This drug candidate, produced from plants, has a unique path. NFL-101 is a protein extract from tobacco leaves. It was initially developed by the Institut Pasteur to fight against allergies that affected workers in contact with these leaves.
The treatment reached the market and was marketed by Stallergenes until 2004. At the same time, it was used without prescription by a French doctor who treated more than 10,000 smokers and showed promising results. .
To the point of encouraging NFL Biosciences to recover the rights to the product from Stallergenes and to continue its development in the fight against smoking. Administered by injection at the time of stopping[…]
